![Paolo Tarantino: Looking forward to join the Medscape symposium to review treatment landscape for HR+/HER2- metastatic breast cancer](https://oncodaily.com/pub/uploads/2024/07/N7-QBrt1_400x400-e1721483692691.png)
Paolo Tarantino: Looking forward to join the Medscape symposium to review treatment landscape for HR+/HER2- metastatic breast cancer
Paolo Tarantino shared a post on LinkedIn:
“Really looking forward to joining this Medscape symposium to review the evolving treatment landscape for HR+/HER2- metastatic breast cancer.
If you’re attending ESMO24 and are interested in breast oncology, please join us!”
Source: Paolo Tarantino/LinkedIn
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023